Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NICE Board Approves Landmark Changes To Increase Flexibility Of Drug Evaluation Methods And Processes In England

Industry Has Mixed Response To “Largest And Most Comprehensive Review”

Executive Summary

Big changes are in store at UK health technology assessment body NICE aimed at improving the way medicines are assessed.

You may also be interested in...



UK Should Look To France To Speed Up Access To Innovative Medicines

Gilead suggests that the UK could take lessons from France on rapidly making innovative new treatments available after approval.

US Industry Hauls Post-Brexit UK Over The Coals

PhRMA wants the UK to be placed on the US Trade Representative’s “Watch List” over issues such as the supplementary protection certificate waiver and delays in access to new drugs caused by “overlapping” cost-containment measures.

Missed Opportunities Punctuate NICE Reform, Says UK Industry

ABPI calls on UK to address lower investments in new medicines compared with comparable markets.

Topics

UsernamePublicRestriction

Register

PS145549

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel